Our observations regarding the differential expression of PSMA upon PI3K inhibition based on PTEN status, and especially the increase in PSMA expression in PTEN-wt prostate cancer cells treated with DS-7423 suggest that this glycoprotein can be utilized as a predictive biomarker of resistance to treatment. Here, FOLH1 is linked to prostate carcinoma.